摘要
目的探讨依达拉奉短期应用对心功能失代偿期扩张型心肌病患者的临床疗效。方法将168例心功能均为Ⅳ级的扩张型心肌病患者随机分为治疗组(86例)和对照组(82例)。治疗组在对照组治疗的基础上加用依达拉奉4周,对比两组治疗前、后心功能改善情况,超声心动图心功能参数变化。结果两组心功能均有改善,治疗组有效率为79.07%,明显高于对照组的39.02%(P<0.05)。治疗后治疗组左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESDD)和左室射血分数(LVEF)较治疗前均显著改善(P<0.01),对照组仅LVEF改善(P<0.01);治疗后两组LVEDD、LVESDD、LVEF比较差异有统计学意义(P<0.05,P<0.01)。结论依达拉奉的应用能在一定程度上改善扩张型心肌病的心功能状态。
Objective To evaluate the clinical therapeutic efficacy of edaravone for decompensation dilated cardiomyopathy. Methods 168 patients（NYHA Ⅳ grade） were divided into two groups in random. 82 patients （control group）with routine treatment, 86 patients （treated group） with routine treatment combining with edaravone for 4 weeks. The therapeutic effect was observed with improvement in NYHA functional class and the cardiac function parameter of echocardiogram. Results The cardiac function grade of NYHA in two groups were improved obv iously, the effective ratio in treated group （79.07%） was significant higher than that in control group （39.02%） （P〈 0.05）. There was obvious imp rovement of LVEDD, LVESDD, LVEF by echocardiogram before and after the treatment （P〈0.01） in treated group, but only LVEF was improved in the control group （P〈0.01）. Moreover,LVEDD, LVESDD, LVEF of two sets were obviously different after treatment （P〈0.05 ,P〈0.01 ）. Conclusion The application of edaravone in compensation dilated cardiomyopathy could improve the cardiac function grade of NYHA.
出处
《中国心血管病研究》
CAS
2008年第9期664-666,共3页
Chinese Journal of Cardiovascular Research
关键词
依达拉奉
扩张型心肌病
疗效
Edaravone
Dilated cardiomyopathy
Efficacy
